REG-4basebio Plc: Directors' Dealings

4BasebioAnnouncement

17/02/2024 21:18

5 February 2024

4basebio plc

(“4babsebio” or the "Company")
 

Directors’ Dealings

Cambridge, UK, 5 February 2024 - 4basebio PLC (AIM: 4BB), an innovation driven
biotechnology company enabling and accelerating development of advanced
therapy medicinal products (ATMPs) through its high performant synthetic DNA
products and non-viral, thermostable nucleic acid delivery platform, announces
that, further to its announcement of 2 February 2024, directors of the Company
have sold shares in order to pay for options exercised as follows:

 Name              Number of Shares Sold  Sale price per share (p)  Shareholding Following Sale  Shareholding as a Percentage of Issued Share Capital  
 Heikki Lanckriet  45,322                 660p                      1,418,994                    11.09%                                                
 David Roth        38,292                 660p                      457,708                      3.58%                                                 

The calculations above are based on an issued share capital of the Company of
12,796,208 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the market abuse
(amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

 4basebio PLC                                      +44 (0)12 2396 7943  
 Heikki Lanckriet, CEO                                                  
                                                                        
 Cairn Financial Advisers LLP (Nominated Adviser)  +44 (0)20 7213 0880  
 Jo Turner / Sandy Jamieson                                             
                                                                        
 Cavendish Capital Markets Limited (Broker)        +44 (0)20 7220 0500  
 Geoff Nash/Charlie Beeson                                              

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014                                                                                                                                              
 1   Details of the person discharging managerial responsibilities/person closely associated                                                                                                                                          
 a.  Name                                                         1. Dr Heikki Lanckriet                                                                                                                                              
                                                                  2. David Roth                                                                                                                                                       
 2   Reason for notification                                                                                                                                                                                                          
 a.  Position/Status                                              1. CEO                                                                                                                                                              
                                                                  2. CFO                                                                                                                                                              
 b.  Initial notification/Amendment                               Initial Notification                                                                                                                                                
 3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                                                    
 a.  Name                                                         4basebio plc                                                                                                                                                        
 b.  LEI                                                          213800E2DX9EAIUNCB30                                                                                                                                                
 4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted                                
 a.  Description of the financial instrument, type of instrument  Ordinary Shares                                                                                                                                                     
     			                                                                                                                                                                                                                              
     			Identification Code                                        ISIN: GB00BMCLYF79                                                                                                                                                 
 b.  Nature of the transaction                                    Sale of Ordinary Shares                                                                                                                                             
                                                                                                           Price(s) per share (p)                   Volume(s)                                                                         
     1. 660p                                                                                               45,322 38,292                                                                                                              
     2. 660p                                                                                                                                                                                                                          
                                                                                                                                                        
 d.  Aggregated information * Volume                              * 83,614                                                                                                                                                            
     * Price                                                      * 660 pence per share                                                                                                                                               
 e.  Date of the transaction                                      2/2/2024                                                                                                                                                            
 f.  Place of the transaction                                     London Stock Exchange, AIM                                                                                                                                          



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved